A Cost-Effectiveness Analysis of Abatacept, Tocilizumab, And Tnf-Inhibitor Compared With Rituximab As A Second-Line Therapy For Treatment of Rheumatoid Arthritis
Abstract
Authors
S Huoponen KJ Aaltonen JT Joensuu J Rutanen H Relas K Taimen K Puolakka T Sokka D Nordström M Blom